兽用皮肤科药物市场 - 全球产业规模、份额、趋势、机会和预测，按适应症、动物类型、给药途径、配销通路、地区和竞争细分，2020-2030F

2024年，全球兽用皮肤科药物市场估值为171.2亿美元，预计在预测期内将达到294.9亿美元，到2030年复合年增长率为9.46%。皮肤科药物市场经历了显着增长宠物皮肤病的发生率和皮肤病患病率的上升。随着世界范围内宠物数量的持续增长，对动物过敏、皮肤炎和感染等常见问题的有效和先进的治疗方法的需求激增。这鼓励製药公司开发更广泛的兽用皮肤病药物，包括口服、外用和注射製剂，兽医诊所和宠物主人越来越容易获得这些药物。对宠物（通常被视为家庭成员）提供专门护理的重视正在推动市场的扩张。特别是，对针对异位性皮肤炎和脓皮病等特定皮肤病的药物的需求导致了药物配方的创新，使治疗更有效且侵入性更小。

市场概况
预测期	2026-2030
2024 年市场规模	171.2亿美元
2030 年市场规模	294.9亿美元
2025-2030 年复合年增长率	9.46%
成长最快的细分市场	过敏感染
最大的市场	北美洲

市场也见证了正在改变兽医皮肤病治疗的主要趋势。重要趋势之一是转向生物製剂和免疫疗法药物，例如单株抗体，事实证明，这些药物在治疗慢性和严重皮肤病方面非常有效。与传统药物相比，这些治疗方法因其针对性强且副作用较少而越来越受欢迎。此外，越来越多地采用营养保健品和自然疗法，包括草药和有机药物，反映出兽医皮肤病学对整体护理的日益偏好。宠物主人越来越关注药物的成分和潜在副作用，并推动更安全的替代方案来管理皮肤状况。

儘管市场成长和进步前景广阔，但仍存在一些阻碍其进步的挑战。主要障碍之一是对宠物皮肤病问题的认识和理解有限，尤其是在新兴经济体。许多宠物主人未能识别皮肤病的早期症状，从而导致治疗延迟并发展为更严重的病症。另一个挑战是专门的兽用皮肤病药物的高昂成本，这可能会限制低收入地区宠物主人的使用。此外，监管挑战和新药审批流程缓慢可能会延迟新疗法的上市，限制市场潜力。透过加强教育和意识以及更实惠的定价策略来应对这些挑战，对于兽用皮肤病药物市场的持续成长至关重要。

主要市场驱动因素

宠物过敏疾病增加

皮肤病治疗的进展

人们对宠物皮肤状况的认识不断增强

主要市场挑战

缺乏临床数据和研究

副作用和安全问题

这些安全问题和副作用是兽医和製药公司必须解决的因素，以确保皮肤科治疗在兽医市场上取得成功。

主要市场趋势

扩大新疗法的监管批准

对生物製品和单株抗体的需求增加

细分市场洞察

动物类型见解

管理途径见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球兽用皮肤科药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依适应症（寄生虫感染、过敏感染、其他）
  • 依动物类型（伴侣动物、牲畜）
  • 依给药途径（局部、口服、注射）
  • 按配销通路（医院药房、零售、电子商务）
  • 按公司划分 (2024)
  • 按地区
• 市场地图

第 6 章：北美兽用皮肤科药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按指示
  • 依动物类型
  • 依给药途径
  • 按配销通路
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲兽用皮肤科药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按指示
  • 依动物类型
  • 依给药途径
  • 按配销通路
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区兽用皮肤科药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按指示
  • 依动物类型
  • 依给药途径
  • 按配销通路
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲兽医皮肤科药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按指示
  • 依动物类型
  • 依给药途径
  • 按配销通路
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲兽医皮肤科药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按指示
  • 依动物类型
  • 依给药途径
  • 按配销通路
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第14章：竞争格局

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale SA
• Boehringer Ingelheim International GmbH
• VETOQUINOL SA
• Bioiberica SAU
• Bimeda Inc.
• Virbac SA
• Vivaldis

第 15 章：策略建议

第16章调查会社について・免责事项

Global Veterinary Dermatology Drugs Market was valued at USD 17.12 Billion in 2024 and is expected to reach USD 29.49 Billion in the forecast period with a CAGR of 9.46% through 2030. The Global Veterinary Dermatology Drugs Market has experienced significant growth, driven by an increasing awareness of skin diseases in pets and the rising prevalence of dermatological conditions. As pet ownership continues to grow worldwide, the demand for effective and advanced treatments for common issues like allergies, dermatitis, and infections in animals has surged. This has encouraged pharmaceutical companies to develop a wider range of veterinary dermatology drugs, including oral, topical, and injectable formulations, which are becoming more accessible to veterinary clinics and pet owners. The emphasis on providing specialized care for pets, who are often considered family members, is fueling the market's expansion. In particular, the demand for drugs that target specific skin conditions like atopic dermatitis and pyoderma has led to innovations in drug formulations, making treatment more effective and less invasive.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 17.12 Billion
Market Size 2030	USD 29.49 Billion
CAGR 2025-2030	9.46%
Fastest Growing Segment	Allergic Infections
Largest Market	North America

The market is also witnessing key trends that are transforming veterinary dermatology treatments. One of the significant trends is the shift towards biologics and immunotherapy drugs, such as monoclonal antibodies, which are proving to be highly effective in managing chronic and severe skin conditions. These treatments are gaining popularity due to their targeted approach and reduced side effects compared to traditional drugs. Moreover, the increasing adoption of nutraceuticals and natural treatments, including herbal and organic drugs, reflects a growing preference for holistic care in veterinary dermatology. Pet owners are becoming more concerned about the ingredients and potential side effects of drugs, pushing for safer alternatives in managing skin conditions.

Despite the promising growth and advancements in the market, there are several challenges hindering its progress. One of the major obstacles is the limited awareness and understanding of dermatological issues in pets, especially in emerging economies. Many pet owners fail to recognize early symptoms of skin diseases, which results in delayed treatment and the development of more severe conditions. Another challenge is the high cost of specialized veterinary dermatology drugs, which may restrict access for pet owners in low-income regions. Additionally, regulatory challenges and the slow approval process for new drugs can delay the availability of novel treatments, limiting market potential. Efforts to address these challenges through increased education and awareness, as well as more affordable pricing strategies, will be crucial for the continued growth of the veterinary dermatology drugs market.

Key Market Drivers

Increase in Allergic Diseases in Pets

The Global Veterinary Dermatology Drugs Market is experiencing significant growth due to the rising incidence of allergic diseases in pets, especially among companion animals. Allergic conditions such as atopic dermatitis, flea allergy dermatitis, and food allergies are becoming increasingly prevalent, particularly in dogs and cats. These diseases cause severe itching, inflammation, and skin irritation, significantly affecting the quality of life for pets. According to recent studies, the prevalence of atopic dermatitis in dogs ranges between 10-15%, with an increasing trend observed in recent years, particularly in developed regions where awareness about pet health is high. This rising burden of allergic conditions has led to an increased demand for effective dermatological treatments.

Pet owners, who now view their animals as family members, are increasingly seeking advanced therapies to manage these chronic skin conditions. This has driven the need for specialized drugs such as corticosteroids, antihistamines, immunosuppressants, and newer biologic treatments like monoclonal antibodies. The growing focus on improving pet healthcare, paired with an increase in the number of veterinary dermatologists, has led to greater accessibility and knowledge of advanced treatments, further propelling the market.

As pets live longer due to improved overall veterinary care, the incidence of allergic conditions is expected to rise, creating a consistent demand for effective dermatology drugs. In response to this growing need, veterinary pharmaceutical companies are continuously investing in research and development, focusing on creating more targeted and effective solutions for managing allergic diseases in pets. The market will continue to expand as these innovative treatments become more available, ensuring better management of allergies and enhancing the quality of life for pets.

Advances in Dermatological Treatments

The Global Veterinary Dermatology Drugs Market is benefiting from significant advances in dermatological treatments, which are enhancing the effectiveness of therapies for pets suffering from various skin conditions. Innovations in treatment modalities, including biologics, topical therapies, and immunosuppressive drugs, have enabled better management of complex dermatological issues like atopic dermatitis, allergic reactions, and infections in animals. These treatments are designed to target specific immune responses, offering long-lasting relief with fewer side effects compared to traditional treatments. The development of monoclonal antibodies and Janus kinase (JAK) inhibitors is revolutionizing the way chronic dermatological conditions are treated in pets, allowing for a more precise approach.

Recent studies have shown that biologics, which were initially used in human medicine, are proving effective for managing severe cases of allergic dermatitis in companion animals. For example, the approval of novel biologic therapies, such as monoclonal antibodies, offers a more targeted way of reducing inflammation and managing skin conditions in pets. These advancements not only improve the quality of life for pets but also provide veterinarians with a wider range of therapeutic options, leading to better treatment outcomes.

The increasing availability of advanced dermatological treatments has led to more proactive care for pets. Pet owners are becoming more aware of the importance of treating skin conditions early to prevent long-term damage. Veterinary dermatology drug manufacturers are focusing on creating easy-to-administer and highly effective solutions, which further boosts the adoption of these advanced treatments in clinical practice. This growth in treatment options and the improved efficacy of available drugs are major factors driving the market's expansion.

Growing Awareness of Pet Skin Conditions

The growing awareness of pet skin conditions is a significant driver for the Global Veterinary Dermatology Drugs Market. As pets increasingly become integral members of families, pet owners are more conscientious about their pets' overall health and well-being, including skin conditions. With more focus on the quality of life of pets, conditions like atopic dermatitis, flea allergies, and infections are being recognized and treated early. This increased awareness is leading to a surge in demand for specialized dermatology treatments and veterinary care.

In 2023, around 10-15% of dogs were reported to have some form of allergic skin condition, with atopic dermatitis being one of the most common, according to a study by the American Animal Hospital Association. This increased recognition is resulting in higher spending on veterinary dermatological services and products. For example, the market for pet skincare products has seen growth of about 6-7% annually in regions like North America, driven by the rising number of pets diagnosed with allergies and eczema.

Veterinarians are also placing a stronger emphasis on preventive dermatology, further boosting demand for targeted drugs. This has led to improved availability of treatments, including topical, oral, and injectable drugs designed specifically for pet dermatology. The rising consumer education about the importance of dermatological health for pets, paired with increased access to veterinary services, is expected to continue driving market growth in the coming years.

Key Market Challenges

Lack of Clinical Data and Research

A significant challenge faced by the Global Veterinary Dermatology Drugs Market is the lack of robust clinical data and research on dermatological conditions in animals. Unlike human dermatology, veterinary dermatology has historically received less attention from researchers and pharmaceutical companies, resulting in limited clinical trials and insufficient evidence on the efficacy and safety of many treatments. This gap in research makes it difficult for veterinarians to make well-informed decisions about treatment options, especially when dealing with complex or rare dermatological conditions in pets.

The shortage of comprehensive clinical data hinders the development and approval of new drugs for veterinary dermatology. For instance, while human dermatology benefits from extensive clinical studies on drug interactions, side effects, and long-term outcomes, similar studies for pets are lacking. Without a strong foundation of clinical data, the adoption of innovative therapies or advanced treatments, such as biologics and gene therapies, is slower in veterinary dermatology.

Additionally, the absence of standardized guidelines and uniform clinical trial protocols for veterinary dermatology further complicates the research landscape. Veterinary dermatology varies significantly across different species, and clinical trials for companion animals often lack consistency in terms of breed, age, and underlying health conditions, which impacts the reliability of study results. This variability in clinical trials makes it difficult to generalize findings to a broader population of animals.

As a result, regulatory agencies may be cautious in approving new dermatology drugs, further delaying market entry. Veterinary professionals are left with limited treatment options and must rely on conventional methods or off-label uses of human medications, which can be less effective or carry higher risks. This lack of clinical data and research is a key challenge that needs to be addressed for the growth and development of the veterinary dermatology drugs market.

Side Effects and Safety Concerns

One of the significant challenges faced by the Global Veterinary Dermatology Drugs Market is the side effects and safety concerns associated with dermatological treatments for animals. Many of the drugs currently used to treat skin conditions, such as steroids and antibiotics, can have adverse effects when used long-term. Corticosteroids, commonly prescribed for allergic skin conditions like atopic dermatitis, are known to cause side effects such as weight gain, increased thirst, urinary frequency, and potential damage to the liver or kidneys with prolonged use. Similarly, antibiotics, though essential for treating infections, can lead to antibiotic resistance if used excessively, creating concerns for both animal health and public health.

For some biologics, such as monoclonal antibodies, the risk of allergic reactions or immune system disruptions remains a concern. While biologics offer targeted treatment with fewer side effects compared to traditional drugs, their long-term safety profile is still being evaluated, and some pets may experience adverse reactions to these treatments. These safety concerns can create hesitancy among veterinarians and pet owners when selecting dermatology drugs, limiting their adoption.

There are also challenges in ensuring the correct use of medications and preventing potential misuse. The improper administration of drugs or non-compliance with prescribed dosages can lead to ineffective treatment or unnecessary side effects. This issue is compounded by a lack of widespread education on the proper use of veterinary dermatological medications among pet owners, resulting in suboptimal outcomes for pets and increased healthcare costs.

These safety concerns and side effects are factors that veterinarians and pharmaceutical companies must address to ensure the success of dermatological treatments in the veterinary market.

Key Market Trends

Expansion of Regulatory Approvals for New Treatments

The expansion of regulatory approvals for new treatments is a significant trend in the Global Veterinary Dermatology Drugs Market. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have become more efficient in approving dermatological treatments for companion animals. This has led to a surge in the availability of advanced drugs that are safe, effective, and specifically tailored to address complex skin conditions in pets, such as atopic dermatitis, allergic reactions, and infections. The streamlined approval processes have facilitated the entry of innovative biologics, including monoclonal antibodies and gene therapies, into the market.

In 2023, the European Medicines Agency (EMA) recommended 14 veterinary medicines for marketing authorization, with nine featuring new active substances, marking a threefold increase compared to 2022.This surge in approvals underscores the industry's commitment to developing innovative solutions for animal health.

Similarly, the U.S. Food and Drug Administration (FDA) has been actively approving new dermatologic drugs. Between 2012 and 2022, the FDA approved 52 new dermatologic drugs, with 11 categorized as first in class and 13 as first in indication. This trend highlights the growing recognition of the need for specialized dermatological treatments in veterinary medicine.

Regulatory agencies are recognizing the growing demand for specialized veterinary dermatology treatments. As a result, there is an increasing emphasis on approving products that not only meet the stringent safety standards but also address the evolving needs of pet owners seeking safer and more effective therapeutic options. For instance, treatments like Lokivetmab (Cytopoint) for canine atopic dermatitis have gained fast-track approvals due to their targeted action and reduced side effects compared to traditional corticosteroids.

This trend has created a robust pipeline of dermatological drugs that promise long-term relief for pets. New treatments are also expanding the therapeutic options available to veterinarians, allowing for more personalized care. As these regulatory approvals continue to accelerate, the veterinary dermatology drugs market is set to witness an influx of novel treatments that will offer better clinical outcomes, improve the quality of life for pets, and enhance veterinary practices' capabilities to address a wide range of skin conditions. The expansion of regulatory approvals is positioning the market for sustained growth and innovation.

Rise in Demand for Biologics and Monoclonal Antibodies

The rise in demand for biologics and monoclonal antibodies in the Global Veterinary Dermatology Drugs Market is transforming the way veterinarians approach the treatment of dermatological conditions in companion animals. Biologics, including monoclonal antibodies, are gaining significant attention due to their ability to provide targeted, effective treatment with fewer side effects compared to traditional therapies. One key product, Lokivetmab (Cytopoint), is a monoclonal antibody used to treat atopic dermatitis in dogs, a condition that causes chronic itching and skin inflammation. Unlike corticosteroids, which can have long-term negative effects, biologics like Lokivetmab directly target the immune pathways responsible for the condition, offering long-lasting relief and improved quality of life for affected animals.

Monoclonal antibodies are becoming a preferred option for conditions such as allergic dermatitis, flea allergies, and other chronic skin diseases that are difficult to treat with conventional medications. The precision of these treatments reduces the risk of unwanted side effects, making them especially attractive to pet owners concerned about the long-term health of their animals. The demand for biologics is further driven by the growing awareness among veterinarians and pet owners about the effectiveness and safety of these advanced therapies.

As the veterinary dermatology market evolves, the introduction of more biologic products tailored to different skin conditions is expected to increase. With increasing regulatory approvals and a deeper understanding of the role of immune modulation in dermatological diseases, the growth of biologics and monoclonal antibodies will continue to play a pivotal role in the management of dermatological disorders in companion animals. This trend reflects the ongoing innovation in veterinary medicine and the focus on delivering highly effective, safe treatment options.

Segmental Insights

Animal Type Insights

Based on the Animal Type, Companion Animals emerged as the dominant segment in the Global Veterinary Dermatology Drugs Market in 2024. This is driven by the increasing pet ownership trends worldwide and growing awareness among pet owners about the importance of veterinary care. The rise in common dermatological issues such as allergies, infections, and dermatitis among pets, especially dogs and cats, has further spurred the demand for effective dermatology treatments. As pets are increasingly treated as family members, owners are more inclined to seek advanced, specialized solutions for skin-related conditions. Companion animals are more susceptible to skin problems due to their close contact with various allergens, parasites, and environmental factors, driving the need for targeted dermatological therapies.

Moreover, with the growing humanization of pets and the increasing willingness to spend on their health, there is a surge in demand for innovative dermatology drugs, such as topical treatments, oral medications, and biologics, which contribute to enhanced quality of life for affected animals. This shift in consumer behavior, combined with the development of advanced veterinary dermatology drugs, has positioned companion animals as the key segment in the veterinary dermatology market. With rising pet care expenditure and a focus on specialized treatments, the segment is expected to continue its dominance in the coming years.

Route of Administration Insights

Based on the Route of Administration, Oral emerged as the dominant segment in the Global Veterinary Dermatology Drugs Market in 2024. This is due to its convenience and effectiveness in treating a wide range of dermatological conditions in animals. Oral medications, such as tablets, capsules, and chewables, offer ease of administration for pet owners, particularly for pets that may be difficult to treat with topical solutions. These drugs are also preferred for their systemic action, as they can address both surface-level and deeper skin conditions, providing comprehensive treatment for conditions like allergies, dermatitis, and infections. The increasing demand for oral dermatology drugs is driven by their ability to offer long-lasting results, with fewer applications needed compared to topical treatments. Oral medications are also less likely to be washed off or ingested by the animals, ensuring consistent dosage and therapeutic effects. Additionally, the convenience of oral treatments has contributed to better compliance with prescribed regimens, especially in pets with chronic dermatological issues that require ongoing care.

Regional Insights

North America emerged as the dominant region in the Global Veterinary Dermatology Drugs Market in 2024. This is largely driven by the high demand for advanced pet healthcare and a growing awareness of dermatological conditions among pet owners. The region's strong veterinary infrastructure, coupled with a well-established pet care industry, has contributed to the widespread availability and adoption of veterinary dermatology drugs. North America's highly developed healthcare system enables quick access to the latest treatments, including innovative dermatological solutions for companion animals.

Increased spending on pet health, particularly in the U.S. and Canada, has fueled growth in the market for veterinary dermatology products. Pet owners in these countries are becoming more proactive in managing their pets' skin health, leading to a rise in consultations for dermatological issues and subsequently a higher demand for specialized drugs. Furthermore, the strong presence of pharmaceutical companies and veterinary clinics offering advanced dermatology treatments has enhanced access to these medications.

The region also benefits from a growing trend of pet humanization, where pets are increasingly treated as family members, leading to a focus on providing them with top-tier medical care. This trend, along with a rise in dermatological disorders like allergies and dermatitis, is expected to sustain North America's dominance in the global veterinary dermatology drugs market.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale S.A.
• Boehringer Ingelheim International GmbH
• VETOQUINOL S.A.
• Bioiberica S.A.U.
• Bimeda Inc.
• Virbac S.A.
• Vivaldis

Report Scope:

In this report, the Global Veterinary Dermatology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Dermatology Drugs Market, By Indication:

• Parasitic Infections
• Allergic Infections
• Others

Veterinary Dermatology Drugs Market, By Animal Type:

• Companion Animals
• Livestock Animals

Veterinary Dermatology Drugs Market, By Route of Administration:

• Topical
• Oral
• Injectable

Veterinary Dermatology Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail
• E-commerce

Veterinary Dermatology Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Dermatology Drugs Market.

Available Customizations:

Global Veterinary Dermatology Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Veterinary Dermatology Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Parasitic Infections, Allergic Infections, Others)
  • 5.2.2. By Animal Type (Companion Animals, Livestock Animals)
  • 5.2.3. By Route of Administration (Topical, Oral, Injectable)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail, E-commerce)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Veterinary Dermatology Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Dermatology Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Mexico Veterinary Dermatology Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Canada Veterinary Dermatology Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Veterinary Dermatology Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Veterinary Dermatology Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Veterinary Dermatology Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Veterinary Dermatology Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Veterinary Dermatology Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Veterinary Dermatology Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Veterinary Dermatology Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Veterinary Dermatology Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Veterinary Dermatology Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. South Korea Veterinary Dermatology Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. Japan Veterinary Dermatology Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Veterinary Dermatology Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. South America Veterinary Dermatology Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Veterinary Dermatology Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Veterinary Dermatology Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Veterinary Dermatology Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Veterinary Dermatology Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Veterinary Dermatology Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Veterinary Dermatology Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Veterinary Dermatology Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Zoetis Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Merck & Co., Inc.
• 14.3. Elanco Animal Health Inc.
• 14.4. Ceva Sante Animale S.A.
• 14.5. Boehringer Ingelheim International GmbH
• 14.6. VETOQUINOL S.A.
• 14.7. Bioiberica S.A.U.
• 14.8. Bimeda Inc.
• 14.9. Virbac S.A.
• 14.10. Vivaldis

15. Strategic Recommendations

16. About Us & Disclaimer